Drugs / Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165
Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06473740 | Jun 2024 → May 2027 expected | limb ischemia | Amur State Medical Academy | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06473740 ↗ |
| Known as | deoxyribonucleic acid plasmid supercoiled pCMV-VEGF165 | “Best endovascular treatment + Introduction Neovasculgen (International nonproprietary or group name: deoxyribonucleic acid plasmid supercoiled pCMV-VEGF165).” NCT06473740 ↗ |
| Known as | Neovasculgen | “Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)” NCT06473740 ↗ |
| Route | Intramuscular | “for intramuscular administration” NCT06473740 ↗ |